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Abstract
Background: In patients with stage II colorectal cancer (CRC) the number of surgically retrieved lymph nodes (LNs)
is associated with prognosis, resulting in a minimum of 10–12 retrieved LNs being recommended for this stage.
Current guidelines do not provide a recommendation regarding LN yield in T1 CRC. Studies evaluating LN yield in
T1 CRC suggest that such high LN yields are not feasible in this early stage, and a lower LN yield might be appropriate.
We aimed to validate the cut-off of 10 retrieved LNs on risk for recurrent cancer and detection of LN metastasis (LNM)
in T1 CRC, and explored whether this number is feasible in clinical practice.
Methods: Patients diagnosed with T1 CRC and treated with surgical resection between 2000 and 2014 in thirteen
participating hospitals were selected from the Netherlands Cancer Registry. Medical records were reviewed to collect
additional information. The association between LN yield and recurrence and LNM respectively were analyzed using 10
LNs as cut-off. Propensity score analysis using inverse probability weighting (IPW) was performed to adjust for clinical
and histological confounding factors (i.e., age, sex, tumor location, size and morphology, presence of LNM,
lymphovascular invasion, depth of submucosal invasion, and grade of differentiation).
Results: In total, 1017 patients with a median follow-up time of 49.0 months (IQR 19.6–81.5) were included.
Four-hundred five patients (39.8%) had a LN yield ≥ 10. Forty-one patients (4.0%) developed recurrence. LN
yield≥ 10 was independently associated with a decreased risk for recurrence (IPW-adjusted HR 0.20; 95% CI 0.06–0.67;
P = 0.009). LNM were detected in 84 patients (8.3%). LN yield≥ 10 was independently associated with increased
detection of LNM (IPW-adjusted OR 2.27; 95% CI 1.39–3.69; P = 0.001).
Conclusions: In this retrospective observational study, retrieving < 10 LNs was associated with an increased risk of
CRC recurrence, advocating the importance to perform an appropriate oncologic resection of the draining LNs
and diligent LN search when patients with T1 CRC at high-risk for LNM are referred for surgical resection. Given
that both gastroenterologists, surgeons and pathologists will encounter T1 CRCs with increasing frequency due to the
introduction of national screening programs, awareness on the consequences of an inadequate LN retrieval is of utmost
importance.
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Background
With the introduction of colorectal cancer (CRC)
screening programs, there has been a shift towards an
increased detection of T1 CRC as compared to more ad-
vanced cancers [1, 2]. Endoscopic resection is considered
curative for low-risk T1 CRC. However, surgical resec-
tion is recommended for patients with T1 CRC with a
considerable risk of lymph node metastasis (LNM), as
determined by histological high-risk factors [3, 4]. The
prognosis of these patients depends to a large extent on
the lymph node (LN) status, with a CRC-related 5-year
survival of ≥ 95% in the absence of LNM (American Joint
Committee on Cancer (AJCC) stage I T1 CRC), decreas-
ing to 68–90% in the presence of LNM (AJCC stage III
T1 CRC) [5, 6].
In contrast to AJCC stage II CRC (T3–4 CRC), in
which a higher LN yield has been associated with im-
proved survival, little is known on the association be-
tween LN yield and recurrence in T1 CRC [7, 8].
Therefore, international guidelines restrict their recom-
mendation for a minimum yield of 10–12 LNs to AJCC
stage II CRC [9–12]. It is questionable whether the rec-
ommended cut-off in advanced CRC can be extrapolated
to T1 CRC, given that more advanced tumor depth has
been associated with an increased LN yield [13–15].
Accordingly, reported LN yields in T1 CRC are much
lower, with mean and median LN yields between 4 and 7
in studies performed between 1988 and 2003 [13, 16–18].
One might hypothesize that the additional value of re-
trieving more LNs might be less relevant for T1 CRCs as
LNM are reported in only 8–12% of patients and re-
currence after surgical resection is reported in only 2–5%
of patients [3, 4, 19]. Two small single-center studies ar-
gued that a minimum of 4 and 8 retrieved LNs, respect-
ively, should be appropriate for staging T1 CRC [16, 20],
whereas La Torre et al. [21] concluded that a limited re-
section does not affect oncological outcome in this early
stage. However, these studies were either small or not in-
formed about long-term recurrence rates.
In this longitudinal multicenter retrospective cohort
study consisting of patients who underwent surgical re-
section of T1 CRC, we aimed to explore the association
between LN yield and the risk for recurrence, and to as-
sess the association between LN yield and the detection
of LNM. Moreover, we aimed to explore whether a mini-
mum of 10 LNs is feasible in a routine clinical setting.
Methods
Patients and study design
This is a multicenter retrospective cohort study. Patients
diagnosed with T1 CRC in 13 participating hospitals (1
academic and 12 non-academic hospitals) between 1
January 2000 and 31 December 2014 were selected from
the Netherlands Cancer Registry. The electronic medical
records of all patients were reviewed. Only cases in
which the local pathologist clearly confirmed the diagno-
sis T1 CRC in the pathology report were selected, which
was defined as tumors with invasion through the muscu-
laris mucosa and into, but not beyond, the submucosa
[22]. Patients were included if they were treated with
surgical resection of T1 CRC. Transanal endoscopic
microsurgery was considered an endoscopic treatment,
as no lymphadenectomy is performed. Exclusion criteria
were hereditary predisposition for CRC, inflammatory
bowel disease, synchronous CRC (defined as CRC in
the previous 5 years before detection of T1 CRC, or
elsewhere in the colorectum at the time of detection of
T1 CRC), non-CRC-related death within 1 year, non-
adenocarcinoma, neo-adjuvant radiotherapy, unknown
number of retrieved LNs, and AJCC stage IV T1 CRC
at diagnosis.
This study was approved by the Medical Ethics Review
Committee of the University Medical Center Utrecht
(reference number 15-487/C) and was carried out in ac-
cordance with the Helsinki Declaration. The study con-
forms to the STROBE guideline for cohort studies [23].
Endpoints
In each participating center, study variables were collected
from the electronic medical records, and the correspond-
ing endoscopy, surgery, pathology, and radiology reports.
Primary endpoint was incidence of recurrent cancer, either
local or distant. Local recurrence was defined as malignant
tissue at the site of the anastomosis. Distant recurrence
was defined as metastasis to extra-colonic organs, bone
or peritoneum confirmed with imaging or histology. A
new primary CRC elsewhere in the colon or rectum was
defined as a metachronous lesion, not as recurrence. Sec-
ondary endpoint was prevalence of LNM at time of sur-
gery, defined as positive LNs in the resection specimen as
reported in the pathology report.
Determinant and confounding factors
The determinant of interest was number of retrieved
LNs, as reported in the pathology reports. We dichoto-
mized LN yield using 10 retrieved LNs as cut-off, as this
is the lowest recommended minimum for AJCC stage II
CRC in current (inter)national guidelines [9, 11, 12].
Established risk factors (based on previous literature)
for recurrent cancer and LNM were considered potential
confounding factors [3, 4, 7, 24]. Data on potential clin-
ical confounders were collected from the medical re-
cords and endoscopy reports, and included age, sex,
tumor location (right colon vs. left colon vs. rectum),
tumor size and tumor morphology (pedunculated vs.
non-pedunculated) [3, 7, 24]. Right colon was defined as
caecum, ascending and transverse colon including the
splenic curve. Left colon was defined as the descending
Backes et al. BMC Medicine  (2017) 15:129 Page 2 of 11
and sigmoid colon. Tumor morphology was defined as
pedunculated if the presence of a stalk or Paris 0-Ip was
reported in the endoscopy report [25]. Flat and sessile
tumors were defined as non-pedunculated T1 CRCs [26].
Potential histological confounders were collected from the
pathology reports, and included lymphovascular invasion
(absent vs. present), depth of submucosal invasion (super-
ficial vs. deep invasion), and grade of differentiation (good
vs. moderate vs. poor) [4]. Deep submucosal invasion was
defined as invasion depth ≥ 1 mm or sm2/3 for non-
pedunculated T1 CRC, and Haggitt 4 for pedunculated T1
CRC [4]. For the endpoint recurrent cancer, the list of po-
tential confounders was extended with LNM as a con-
founding factor [7].
Additional patient characteristics (not causally related
to recurrent cancer or LNM and therefore not considered
potential confounders) and follow-up characteristics were
collected from medical records. Patient characteristics
were body mass index (calculated as weight in kilograms
divided by height in meters squared) and comorbidity ac-
cording to the American Society of Anesthesiologists
Physical Status classification [27]. Follow-up was per-
formed according to routine clinical care. Follow-up
started at the date of diagnosis and ended at the date of
detection of recurrence, death, or last follow-up.
Statistical analysis
Categorical data were expressed as frequencies and per-
centages; continuous variables as means with standard
deviation (SD) or medians with interquartile range (IQR).
Primary aim of this study was to evaluate the associ-
ation between number of retrieved LNs and recurrent
cancer. Despite our large multicenter cohort of patients
spanning an inclusion period of many years, the absolute
number of recurrences was expected to be small, since
recurrent cancer after surgical resection of T1 CRC is a
rare event. We therefore used propensity scores allowing
for the adjustment for more confounders than would
have been feasible using standard multivariable adjust-
ment approaches [28–30]. Inverse probability weighting
(IPW) was used to account for baseline differences in
predictive characteristics between patients with LN yield
< 10 vs. ≥ 10. A propensity score was derived by fitting a
logistic regression model with the dichotomized number
of retrieved LNs as the dependent variable and potential
confounders as predictors. We adjusted for confounders
in a two-step approach. For the primary analysis, we ad-
justed for clinical confounding factors (i.e., age, sex,
tumor location, tumor size, tumor morphology, and
presence of LNM). Secondary supporting analyses were
performed to additionally correct for histological con-
founding factors (i.e., lymphovascular invasion, depth of
submucosal invasion, grade of differentiation), which
were not included in the primary analysis as they were
missing in a considerable number of cases (Table 1).
Continuous variables (i.e., age and tumor size) were fit-
ted in the propensity models by restricted cubic spline
functions, dummies were used for categorical variables
(no interaction terms). Then, the inverse of the (propen-
sity score-derived) predicted probability for actual LN
yield was used to weigh patients in a Cox regression
model relating the dichotomized LN yield as the sole de-
terminant of recurrent cancer, yielding hazard ratios
(HR) for a high (≥10) vs. low (< 10) retrieval of LNs.
Patients who did not develop recurrent cancer were cen-
sored at the last follow-up moment or date of death. No
violation of the proportionality of the hazard assumption
was observed following inspection of the scaled Schoen-
feld residuals. Bootstrapping was performed to obtain
two-sided P values and 95% confidence intervals (CI) for
IPW-derived estimates.
Assuming that a low LN yield risks understaging and
these understaged patients would fail to receive chemo-
therapy that could prevent recurrence [31], we additionally
repeated our main analysis restricted to patients in whom
no LNM were observed [32]. Analyses were performed in
the same manner with IPW analysis as described above,
adjusting for the same potential confounders.
Furthermore, to assess the sensitivity of our results for
the way we dichotomized LN yield in our analyses, the
number of retrieved LNs was also analyzed continuously
in univariable regression analyses. Moreover, sensitivity
analyses were performed using 12 retrieved LNs as cut-
off (using similar analysis as used for 10 retrieved LNs as
cut-off ), as this cut-off is often used as a quality measure
for adequate staging in AJCC stage II CRC [9].
Several checks were performed to evaluate the appropri-
ateness of the IPW analysis, namely (1) baseline character-
istics before and after IPW adjustment for confounders
were compared; (2) the c-index of the propensity models
was assessed using the propensity model’s own IPWs (a
c-index of 0.5 indicates a successfully obtained balance
of confounders after adjusting; a c-index of 1.0 indicates ex-
treme remaining imbalance); and (3) the maximum weight
of a single patient used in the IPW-adjusted analysis to ob-
tain balance in potential confounders was assessed as a
quality instrument to assess whether a single or a few cases
influence the risk estimate excessively [33, 34].
The secondary aim was to explore the association be-
tween LN yield and detection of LNM. Like recurrence,
a low number of LNM were observed. Therefore, ana-
lyses were performed in the same manner with IPW
analysis as described above with the presence of LNM as
the endpoint, correcting for the same confounders ex-
cept for the presence of LNM itself. Inverse probability
weighted logistic regression analysis was used yielding
odds ratios (OR) for a high (≥ 10) vs. low (< 10) retrieval
of LNs on the outcome LNM.
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Information on LN yield and the presence of LNM
was available for all patients; however, several clinico-
pathological confounding variables had missing data
(Table 1). As simply excluding patients with missing data
is inefficient and increases the risk of selection bias, we
used multiple imputation before data analysis [35]. Miss-
ing data was assumed to be missing at random. Multi-
variate imputation by chained equations (10 imputation
datasets, 25 iterations, healthy convergence) was per-
formed [36]. Rubin’s rules were used to pool results
across imputation datasets [37]. Percentage of complete
cases (i.e., percentage of patients with no imputed
values) were reported for each analysis, together with
the percentage of observed data points. For the primary
outcome, a sensitivity analysis excluding patients with
missing values was performed (complete-case analysis)
to determine whether this agreed with the imputed re-
sults (Additional file 1: Table S1).
GraphPad Prism version 6.02 (GraphPad software Inc.,
San Diego, CA, USA) was used to draw figures. IBM
SPSS Statistics version 21 (SPSS Inc., Chicago, IL, USA)
and R version 3.2.2 (RStudio Inc., Boston, MA, USA) were
used for statistical analysis. A two-sided P value < 0.05 was
considered significant.
Results
Patient characteristics
A total of 2253 patients with T1 CRC diagnosed between
2000 and 2014 were identified in the participating hospi-
tals. A total of 1017 patients treated for pT1 CRC with
surgical resection remained eligible for analysis (Fig. 1).
Mean age of the cohort was 69.1 years (SD 9.6) and
54.6% of patients were male. A total of 405 patients
(39.8%) had a LN yield ≥ 10. An overview of the baseline
characteristics of patients with a LN yield < 10 vs. ≥ 10
before and after IPW adjustment for the confounders
considered for the primary analysis (adjustment for clin-
ical factors) and the secondary supporting analysis (adjust-
ment for clinical and histological factors) is provided in
Table 1. Before adjustment by IPW, patients with a LN
yield ≥ 10 had T1 CRCs that were more often located in
the right colon (37.5% vs. 15.2%, P < 0.001), had more
often a non-pedunculated morphology (75.9% vs. 60.7%,
P < 0.001), had a larger tumor size (2.9 vs. 2.6 cm, P =
0.003), more often had LNM (11.6% vs. 6.0%, P = 0.002),
and less often showed lymphovascular invasion (20.2% vs.
29.9%, P = 0.04). Following adjustment, baseline character-
istics between groups were comparable.
LN yield in a routine clinical setting
Median LN yield was 7 (IQR 3–12; range 0–52). Median
LN yield increased over time from 4 (IQR 2–8) from
2000 to 2009 (N = 574) to 11 (IQR 7–15) from 2010 to
2014 (N = 443) (P < 0.001). If a minimum of 10 LNs re-
trieved was considered an adequate resection, this thresh-
old value was achieved in 19.5% (112/574) of patients
treated before 2010 versus 66.1% (293/443) of patients
treated from 2010 onwards (P < 0.001). A scatterplot of
LN retrieval over the years is presented in Fig. 2.
LN yield and recurrence
During the 4581 person-years of follow-up (median
49.0 months; IQR 19.6–81.5), 41 patients (4.0%) were di-
agnosed with recurrent cancer, corresponding to 9.0
events (95% CI 6.5–12.0) per 1000 person years of follow-
up (Table 2). Recurrences occurred most frequently in
distant organs (N = 23), followed by local (N = 11) or
both local and distant recurrences (N = 7). Distant me-
tastases were most often located in lung (N = 13) and
liver (N = 16). Recurrences were detected after a median
duration of 26.9 months (IQR 13.9–44.4).
Among 612 patients in whom < 10 LNs were retrieved,
37 patients (6.0%) developed recurrence. Among 405
patients in whom ≥ 10 LNs were retrieved, 4 patients
(1.0%) developed recurrence (Table 2). In univariable
analysis, LN yield ≥ 10 was associated with decreased
risk for recurrence (unadjusted HR 0.27; 95% CI 0.10–
0.76; P = 0.01) (Table 3). After adjustment for clinical
Fig. 1 Study flowchart. AJCC American Joint Committee on Cancer; CRC colorectal cancer; LN lymph node
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confounders (i.e., age, sex, tumor location, tumor size,
tumor morphology, and presence of LNM), LN yield ≥
10 remained associated with a decreased risk for recur-
rence (adjusted HR 0.19; 95% CI 0.06–0.60; P = 0.005).
Findings persisted after further adjusting for histological
factors (adjusted HR 0.20; 95% CI 0.06–0.67; P = 0.009).
Sensitivity analysis excluding patients with imputed
values did not alter the outcomes (Additional file 1:
Table S1).
In patients without LNM (N = 933 patients; N = 35
recurrences), LN yield ≥ 10 remained associated with
decreased risk for recurrence, also after adjusting for
clinicopathological factors (adjusted HR 0.23; 95% CI
0.06–0.81; P = 0.02). Kaplan–Meier curves of recurrence-
free patients stratified for LN yield (< 10 vs. ≥ 10) and
LNM (presence vs. absence) are presented in Fig. 3.
To assess the sensitivity of our results for the way we
dichotomized LN yield, sensitivity analyses were per-
formed with the number of retrieved LNs without
thresholds and using 12 LNs as cut-off. Without thresh-
olds, LN yield remained associated with a decreased risk
for recurrence (per retrieved LN: HR 0.90; 95% CI 0.84–
0.97; P = 0.007). Of the 749 patients in whom < 12 LNs
were retrieved, 37 patients (4.9%) developed recurrences.
Of the 268 patients in whom ≥ 12 LNs were retrieved, 4
patients (1.5%) developed recurrences. Similar to a LN
yield ≥ 10, the HR of a LN yield ≥ 12 pointed towards a
decreased risk for recurrence, albeit non-significant (ad-
justed HR 0.41; 95% CI 0.12–1.34; P = 0.14) (Additional
file 1: Table S2).
LN yield and LNM
LNM were detected in 84 patients, corresponding to a
prevalence of 8.3% (84/1017) (Table 2); 1 positive LN
was detected in 54 patients, 2 in 18 patients, 3 in 4 pa-
tients, and ≥ 4 in 8 patients, with a maximum of 8 posi-
tive LNs per patient. In 6 patients with LNM, recurrence
occurred during follow-up. In univariable analysis, the
number of retrieved LNs (without thresholds) was asso-
ciated with increased detection of LNM (per retrieved
LN: OR 1.04; 95% CI 1.01–1.07; P = 0.006).
LNM were detected in 37 patients (6.0%) with a LN
yield < 10 and in 47 patients (11.6%) with a LN yield ≥ 10
(Table 2). In univariable analysis, LN yield ≥ 10 was posi-
tively associated with increased detection of LNM (un-
adjusted OR 2.04; 95% CI 1.30–3.20; P = 0.002) (Table 4).
After adjusting for clinical confounding factors, LN
yield ≥ 10 remained associated with increased detection
of LNM (adjusted OR 2.09; 95% CI 1.28–3.42). Further
adjusting for histological confounding factors did not
alter the outcomes (adjusted OR 2.27; 95% CI 1.39–
3.69; P = 0.001).
Discussion
To the best of our knowledge, this is the first large-scale
study evaluating the association between LN yield and
long-term recurrence rates in patients with T1 CRC
when adjusting for multiple confounding factors. A LN
yield < 10 was associated with an increased risk for re-
currence after surgical resection of T1 CRC, even when
adjusting for clinical and histological characteristics. Fur-
thermore, LN yield ≥ 10 was independently associated
with an increased detection of LNM. These findings
underline the importance of performing an appropriate
oncologic resection of the draining LNs and diligent LN
search by the pathologist when patients with T1 CRC at
high-risk for LNM are referred for surgical resection and
Fig. 2 Scatterplot of LN retrieval in T1 CRC over the years. Each dot
represents one patient. The squares indicate the median LN yield
per year
Table 2 Recurrent cancer and LNM in T1 CRC, stratified for LN yield (< 10 vs. ≥ 10)
Recurrent cancer LNM
N N (%) Total person-years of follow-up Rate/1000 person-years of follow-up (95% CI) N (%)
Total cohort 1017 41 (4.0) 4581 9.0 (6.5–12.0) 84 (8.3)
LN yield < 10 612 37 (6.0) 3403 10.9 (7.8–14.8) 37 (6.0)
LN yield≥ 10 405 4 (1.0) 1179 3.4 (1.1–8.2) 47 (11.6)
CI confidence interval, CRC colorectal cancer, LN lymph node, LNM lymph node metastasis
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Table 3 Unadjusted and adjusted association between LN yield (≥ 10 vs. < 10) and recurrent cancer after surgical resection
of T1 CRC
Hazard ratio
(95% CI)
P value Maximum (97.5th percentile)
IPWc
Post-IPW
c-indexd
Complete
case (%)e
Observed data
points (%)f
Total cohort
N = 1017
Unadjusted 0.27 (0.10–0.76) 0.01 – – 100 100
Adjusted for clinical factorsa 0.19 (0.06–0.60) 0.005 5.4 (4.4) 0.48 88 98
Adjusted for clinical &
histological factorsb
0.20 (0.06–0.67) 0.009 7.1 (4.4) 0.50 18 88
LN negative
patients
N = 933
Unadjusted 0.25 (0.08–0.83) 0.02 – – 100 100
Adjusted for clinical factorsa 0.21 (0.06–0.77) 0.02 5.6 (4.5) 0.48 88 98
Adjusted for clinical &
histological factorsb
0.23 (0.06–0.81) 0.02 7.1 (4.5) 0.49 17 87
CI confidence interval, CRC colorectal cancer, IPW inverse probability weighting, LN lymph node
aAge (continuously), sex (male vs. female), tumor location (right colon vs. left colon vs. rectum), tumor size (continuously), tumor morphology (pedunculated vs.
non-pedunculated) and lymph node metastasis (presence vs. absence) (the latter only in the total cohort, not in the analysis with LN-negative patients)
bAge (continuously), sex (male vs. female), tumor location (right colon vs. left colon vs. rectum), tumor size (continuously), tumor morphology (pedunculated vs.
non-pedunculated), invasion depth (deep vs. superficial submucosal invasion), lymphovascular invasion (presence vs. absence), differentiation grade (poor vs.
moderate vs. good), and lymph node metastasis (presence vs. absence) (the latter only in the total cohort, not in the analysis with LN-negative patients)
cThe maximum weight of a single patient used in the IPW adjusted analysis to obtain balance in potential confounders. This is a quality instrument to assess
whether a single or a few cases influence the risk estimate excessively. As a rule of thumb this should be lower than 10% of the analyzed dataset (i.e., smaller
than 100 and 90 for the total cohort and LN-negative patients, respectively)
dThis is an estimate of the balance of confounders after adjusting by inverse probability weighting (0.50 complete balance, 1.00 complete unbalance)
ePercentage of complete cases (i.e., cases with no imputed values for any of the evaluated variables of that analysis). Note: analysis was performed on the
imputed dataset concerning all cases
fPercentage of available data points before imputation. Note: analysis was performed on the imputed dataset concerning all cases
Fig. 3 Kaplan–Meier curve of percentage of recurrence-free T1 CRC patients in relation to LN yield and presence of LNM. Green line: patients with
T1 CRC without LNM and LN yield≥ 10; orange line: patients with T1 CRC (with and without LNM) and LN yield≥ 10; purple line: patients with T1
CRC without LNM and LN yield < 10; blue line: patients with T1 CRC (with and without LNM) and LN yield < 10; red line: patients with T1 CRC with
LNM (irrespective of LN yield). The inset shows the same data on an enlarged y axis. Abbreviations: CRC: colorectal cancer; LN: lymph node; LNM:
lymph node metastasis; nr: number
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question the legitimacy of a limited resection for these
patients.
In contrast to earlier smaller studies, we validated a
cut-off (≥ 10) that was chosen based on current recom-
mendations for AJCC stage II CRC, instead of evaluating
multiple study-specific cut-off points and selecting the
most suitable one [16, 20]. This approach is less prone
to the introduction of overestimation of the difference
in outcomes between groups, and enhances the
generalizability and external validity of the results [38].
To assess the sensitivity of our results for the manner
in which the LN yield was dichotomized, we performed
sensitivity analyses with the number of retrieved LNs
analyzed continuously and additionally used 12 retrieved
LNs as the cut-off. In all analyses, the HR indicated a de-
creased risk for recurrence.
Our findings build on a study conducted with data from
the Surveillance, Epidemiology, and End Results cancer
registry in patients with AJCC stage I CRC, comprising
both T1N0 and T2N0 CRC [31]. An increased LN yield
was associated with improved overall survival. However,
this study used a population-based registry, and could
therefore only evaluate the association between LN
yield and mortality due to all causes. As the vast major-
ity (≥ 95%) of patients with T1 CRC without LNM do
not die as a result of CRC, recurrence rates rather than
survival rates are informative when evaluating factors
associated with prognosis in this early stage [5, 6].
Several explanations can be hypothesized for the ob-
served association with recurrence. The first is understa-
ging, with positive nodes missed when an insufficient
number of LNs is retrieved. Consequently, chemother-
apy will not be considered in these patients and the
missed residual cancer cells may metastasize to distant
organs. Evidence on the benefit of chemotherapy in patients
with T1 CRC with LNM is limited. However, it is currently
advised in these patients [39]. Our finding that ≥ 10
retrieved LNs resulted in a significantly higher percentage
of nodal positive patients supports this explanation, as was
also demonstrated in previous work for advanced CRC
stages [31, 40]. However, a population-based retrospective
observational study questioned this mechanism as the
main cause of the observed association, as patients with
higher LN yields were only slightly more likely to have
LNM, suggesting that some other unmeasured factors re-
sulted in better patient outcomes [8]. It has been hypothe-
sized that the number of retrieved LNs might reflect
tumor biology [41]. The tumor microenvironment and the
host’s immune response have been shown to be of major
importance in tumor progression [42]. Thus, a higher LN
yield may reflect a stronger immune response, reducing
the risk for recurrence.
Some limitations should be mentioned. Although the
present cohort is one of the largest on T1 CRCs to date
with long-term follow-up enabling the evaluation of the
association between LN yield and recurrence when
adjusting for multiple confounding factors, it is an ob-
servational study on a retrospective cohort. Inherent to
the design, we had to deal with missing data. Informa-
tion on histological potential confounders was missing
in a considerable number of patients, resulting in one
or more variables having to be imputed in more than
82% of patients in the secondary supporting analysis.
Nevertheless, the estimates resulting from the second-
ary analyses with and without imputation were similar,
suggesting that selection bias due to missingness – if
present – was rather limited (results without imput-
ation can be found in Additional file 1: Table S1). Fur-
thermore, due to the retrospective design, no data was
available on the effort of the surgeon for adequate
lymphadenectomy, such as the extent of the mesentery
excised, and no standardized pathologic evaluation of
the resection specimen was performed. This could have
shed some light on the role of the surgeon and pathologist
Table 4 Unadjusted and adjusted association between LN yield (≥ 10 vs. < 10) and detection of LNM in T1 CRC
Odds ratio
(95% CI)
P value Maximum
(97.5th percentile) IPWc
Post-IPW
c-indexd
Complete
case (%)e
Observed data
points (%)f
Unadjusted 2.04 (1.30–3.20) 0.002 – – 100 100
Adjusted for clinical factorsa 2.09 (1.28–3.42) 0.003 5.1 (4.2) 0.48 88 98
Adjusted for clinical and histological factorsb 2.27 (1.39–3.69) 0.001 6.6 (4.3) 0.49 18 85
CI confidence interval, CRC: colorectal cancer,IPW inverse probability weighting, LN lymph node, LNM lymph node metastasis
aAge (continuously), sex (male vs. female), tumor location (right colon vs. left colon vs. rectum), tumor size (continuously), and tumor morphology (pedunculated
vs. non-pedunculated)
bAge (continuously), sex (male vs. female), tumor location (right colon vs. left colon vs. rectum), tumor size (continuously), tumor morphology (pedunculated vs.
non-pedunculated), invasion depth (deep vs. superficial submucosal invasion), lymphovascular invasion (presence vs. absence), and differentiation grade (poor vs.
moderate vs. good)
cThe maximum weight of a single patient used in the IPW adjusted analysis to obtain balance in potential confounders. This is a quality instrument to assess
whether a single or a few cases influence the risk estimate excessively. As a rule of thumb this should be lower than 10% of the analyzed dataset (i.e., smaller
than 100)
dThis is an estimate of the balance of confounders after adjusting by inverse probability weighting (0.50 complete balance, 1.00 complete unbalance)
ePercentage of complete cases (i.e., cases with no imputed values for any of the evaluated variables of that analysis). Note: analysis was performed on the
imputed dataset concerning all cases
fPercentage of available data points before imputation. Note: analysis was performed on the imputed dataset concerning all cases
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on the LN yield. However, the primary aim of this study
was to explore the association between LN yield and re-
currence in T1 CRC, not to explore the influence of the
pathologist and surgeon, as has been done in previous
studies [17, 43–46]. Taking the results of these studies into
account, we believe LN yield is a shared responsibility of
both surgeon and pathologist.
Secondly, although we corrected as efficiently as pos-
sible for the measured confounders, it remains unclear
how well the unmeasured confounders have been ad-
justed for. New predictive markers in CRC have been
identified in the past two decades, including tumor bud-
ding as prognostic marker for LNM and macroscopic
pathological assessment of the quality of the circumfer-
ential resection margin (CRM) as a prognostic marker
for recurrence in rectal cancer [4, 47, 48]. Standardized
pathologic reporting of the quality of the CRM was only
introduced in Dutch guidelines in recent years, and con-
sensus on the standardized assessment of tumor budding
has only recently been achieved (International Tumor
Budding Consensus Conference 2016) [49]. Therefore,
this hampered the evaluation of these factors in our ana-
lysis. To explore the magnitude of potential bias intro-
duced by lack of information on the quality of the CRM,
we repeated the main analysis when excluding patients
with rectal T1 cancer, yielding similar results, suggesting
that the introduced potential bias is limited (Additional
file 1: Table S3).
Thirdly, we were not informed on tumor biology such
as genetic mutations, microsatellite instable status, or
consensus molecular subtype classification [50, 51].
However, similar to data from the Surveillance, Epi-
demiology, and End Results cancer registry, we ob-
served an increased LN yield over the years,
suggesting that the observed survival benefit cannot
be completely attributed to tumor biology [8, 9]. It is
not unlikely that the Dutch Surgical Colorectal Audit,
introduced in 2008, and the implementation of LN
yield as a quality indicator in 2009 have contributed to
the observed increment in LN yield from 2010 on-
wards. This finding shows that retrieving higher num-
ber of LNs is achievable in daily clinical practice, and
should be aimed for. Moreover, a previous study ob-
served that LN retrieval differed between different
types of hospitals, suggesting that other quality issues
may influence LN retrieval [52].
Finally, it should be emphasized that, despite our mul-
ticenter cohort spanning an inclusion period of many
years, the absolute number of patients with recurrent
cancer or LNM was still low. Although we resorted to
statistical analysis techniques suited for such data and
performed several checks to evaluate the appropriateness
of our analysis, the low number of events unavoidably
resulted in relatively broad CIs.
Conclusion
In conclusion, in this observation cohort study, the re-
trieval of less than 10 LNs was associated with an in-
creased risk for recurrence and decreased detection of
LNM in T1 CRC. Given that gastroenterologists, sur-
geons and pathologists will all encounter T1 CRCs with
increasing frequency due to the introduction of CRC
screening programs, awareness on the consequences of
an inadequate LN retrieval is of utmost importance.
Additional file
Additional file 1: Table S1. Sensitivity analysis comparing the complete
case hazard ratio and the multiple imputation hazard ratio for the
association between lymph node (LN) yield ≥ 10 versus < 10 and the
primary outcome recurrent cancer. Table S2. Unadjusted and adjusted
association between LN yield ≥ 12 (N = 268 patients, N = 4 recurrences)
versus LN yield < 12 (N = 749 patients, N = 37 recurrences) and recurrent
cancer after surgical resection of T1 colorectal cancer. Table S3. Main
analysis restricted to patients with T1 colon cancer (843 T1 colon cancers
with 29 recurrences) in order to explore the magnitude of potential bias
introduced by lack of information on the quality of the circumferential
resection margin in rectal T1 cancer. (DOCX 18 kb)
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